

## Richard Girling

Partner, Centerview Partners

Richard Girling is one of Europe's leading healthcare bankers with over 30 years of experience. Mr. Girling has advised on many of the largest global healthcare transactions including: AstraZeneca in its \$39bn acquisition of Alexion and its \$15bn acquisition of MedImmune, Sanofi's \$73bn acquisition of Aventis and its \$1.9bn acquisition of Kadmon, the \$24bn LBO of Alliance Boots plc and its subsequent \$27bn sale to Walgreens and Vifor Pharma on its \$12bn sale to CSL. Mr. Girling established the European business of Centerview Partners in London in 2009. Since the creation of the Healthcare practice at Centerview Partners, the Healthcare team has advised on a number of significant transactions including: Walgreens Boots Alliance on the \$6.5bn sale of its Alliance Healthcare businesses to AmerisourceBergen, Servier on its acquisition of the 49% minority stake in Egis, CSL on its acquisition of Aventis Behring and its acquisition of Novartis' influenza vaccines business, Hikma on its acquisition of Boehringer Ingelheim's Roxane Laboratories, Aspen on the sale of its infant nutritionals business, NeuroDerm on its \$1.1bn sale to Mitsubishi Tanabe, Galenica on its \$2bn IPO of Galenica Santé and separation of Vifor Pharma, Takeda on its acquisition of TiGenix and Arvelle Therapeutics on its \$960mm sale to Angelini Pharma. Mr. Girling established Merrill Lynch's European healthcare practice in 1998, and was Global Co-Head of Healthcare investment banking for the last six of those years. Following the acquisition by Bank of America, he was appointed the head of the merged Europe, Middle East and Asia (EMEA) and Asia-Pacific healthcare practices for the combined organization. Mr. Girling joined Merrill Lynch in 1998 from Salomon Brothers, where he worked from 1989 to 1998 and was head of the European Pharmaceutical and Healthcare team. Mr. Girling is a member of the Development Board, St Anne's College, Oxford University and a member of the Executive Advisory Board for the Centre for Personalised Medicine at Oxford University. Mr. Girling holds a B.A. and M.A. degrees in Biochemistry from Oxford University.